How the relationship between two proteins affects liver fat and diabetes risk
Impact of inverse relationship between TP53 and CARF on the development of hepatic steatosis and insulin resistance
This study is looking at how two proteins, TP53 and CARF, work together and affect liver fat and insulin resistance, which are important for understanding type 2 diabetes and heart disease, and it hopes to find new ways to help people with these conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Charles R. Drew University of Med & Sci NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11081694 on NIH RePORTER |
What this research studies
This research investigates the connection between two proteins, TP53 and CARF, and their impact on liver fat accumulation and insulin resistance, which are critical factors in the development of type 2 diabetes and cardiovascular diseases. By exploring how these proteins interact under metabolic stress, the study aims to uncover the molecular mechanisms that lead to nonalcoholic fatty liver disease (NAFLD) and insulin resistance. Patients may benefit from insights that could lead to new treatment strategies for managing these conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with obesity, type 2 diabetes, or nonalcoholic fatty liver disease.
Not a fit: Patients without obesity, diabetes, or liver-related conditions may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches for preventing or treating liver fat accumulation and insulin resistance in patients.
How similar studies have performed: Previous research has shown promising results in understanding the roles of p53 and CARF in metabolic diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
Los Angeles, United States
- Charles R. Drew University of Med & Sci — Los Angeles, United States (Active)
Researchers
- Principal investigator: Hasan, Kamrul M — Charles R. Drew University of Med & Sci
- Study coordinator: Hasan, Kamrul M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.